Novartis CEO dances around price tag talks for breakthrough gene therapy

Days before Novartis is expected to win approval for its breakthrough spinal muscular atrophy treatment, the drugmaker ' s CEO said he could justify charging up to $5 million for the revolutionary treatment — but that the goal is to set the cost at " a fraction of what is the current standard of care. "
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news